News of Note—Inovio's MERS vaccine, Inimmune's NIH grant and more

non
(Pixabay)

Here is some other vaccine news of note for the week:

> In a phase 1 study, Inovio and GeneOne Life Science's MERS vaccine, dubbed INO-4700, induced high levels of antibody responses in roughly 95% of subjects and generated broad-based T-cell responses in nearly 90% of study participants. Release

> The University of Montana and startup Inimmune landed a $5.4 million grant from the NIH to develop a vaccine to fight the P. aeruginosa bacteria. Missoula Current article

> Allergy Therapeutics’ grass pollen allergy vaccine Pollinex Quattro Grass showed significant and long-lasting symptom improvements three to six years after cessation of treatment. Precision Vaccinations article

 

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.